Literature DB >> 19417863

Resistant hypertension.

Sheldon W Tobe1, Richard Lewanczuk.   

Abstract

Resistant hypertension is most often due to insufficient medical therapy. With a patient history, physical examination and focused laboratory tests, sufficient information can be gathered to lead to further directed medical therapy, which most often includes a diuretic as part of the drug regimen. Patients may require four or more classes of antihypertensives, some at high doses to achieve control. The clinician must be prepared to use sufficient medications at sufficient doses to achieve blood pressure targets. Referral to a hypertension specialist is appropriate if blood pressure remains uncontrolled despite therapy with three antihypertensive medications.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19417863      PMCID: PMC2707174          DOI: 10.1016/s0828-282x(09)70496-9

Source DB:  PubMed          Journal:  Can J Cardiol        ISSN: 0828-282X            Impact factor:   5.223


  22 in total

1.  Hyperaldosteronism among black and white subjects with resistant hypertension.

Authors:  David A Calhoun; Mari K Nishizaka; Mohammad A Zaman; Roopal B Thakkar; Paula Weissmann
Journal:  Hypertension       Date:  2002-12       Impact factor: 10.190

2.  Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT).

Authors:  William C Cushman; Charles E Ford; Jeffrey A Cutler; Karen L Margolis; Barry R Davis; Richard H Grimm; Henry R Black; Bruce P Hamilton; Joanne Holland; Chuke Nwachuku; Vasilios Papademetriou; Jeffery Probstfield; Jackson T Wright; Michael H Alderman; Robert J Weiss; Linda Piller; Judy Bettencourt; Sandra M Walsh
Journal:  J Clin Hypertens (Greenwich)       Date:  2002 Nov-Dec       Impact factor: 3.738

3.  Results of the Controlled ONset Verapamil INvestigation of Cardiovascular Endpoints (CONVINCE) trial by geographical region.

Authors:  Henry R Black; William J Elliott; Gregory Grandits; Patricia Grambsch; Tracy Lucente; James D Neaton; Richard H Grimm; Lennart Hansson; Yves Lacourcière; James E Muller; Peter Sleight; Michael A Weber; William B White; Gordon H Williams; Janet Wittes; Alberto Zanchetti; Robert J Anders
Journal:  J Hypertens       Date:  2005-05       Impact factor: 4.844

4.  Resistant hypertension revisited: a comparison of two university-based cohorts.

Authors:  Jay P Garg; William J Elliott; Amy Folker; Munavvar Izhar; Henry R Black
Journal:  Am J Hypertens       Date:  2005-05       Impact factor: 2.689

5.  Cardiovascular outcome in treated hypertensive patients with responder, masked, false resistant, and true resistant hypertension.

Authors:  Sante D Pierdomenico; Domenico Lapenna; Anna Bucci; Roberta Di Tommaso; Rocco Di Mascio; Bianca M Manente; Maria P Caldarella; Matteo Neri; Franco Cuccurullo; Andrea Mezzetti
Journal:  Am J Hypertens       Date:  2005-11       Impact factor: 2.689

6.  Resistance to antihypertensive medication as predictor of renal artery stenosis: comparison of two drug regimens.

Authors:  B C van Jaarsveld; P Krijnen; F H Derkx; J Deinum; A J Woittiez; C T Postma; M A Schalekamp
Journal:  J Hum Hypertens       Date:  2001-10       Impact factor: 3.012

7.  Resistant hypertension in a tertiary care clinic.

Authors:  M Yakovlevitch; H R Black
Journal:  Arch Intern Med       Date:  1991-09

8.  Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial.

Authors:  Stevo Julius; Sverre E Kjeldsen; Michael Weber; Hans R Brunner; Steffan Ekman; Lennart Hansson; Tsushung Hua; John Laragh; Gordon T McInnes; Lada Mitchell; Francis Plat; Anthony Schork; Beverly Smith; Alberto Zanchetti
Journal:  Lancet       Date:  2004-06-19       Impact factor: 79.321

9.  The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report.

Authors:  Aram V Chobanian; George L Bakris; Henry R Black; William C Cushman; Lee A Green; Joseph L Izzo; Daniel W Jones; Barry J Materson; Suzanne Oparil; Jackson T Wright; Edward J Roccella
Journal:  JAMA       Date:  2003-05-14       Impact factor: 56.272

Review 10.  The 2009 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 1--blood pressure measurement, diagnosis and assessment of risk.

Authors:  Raj S Padwal; Brenda R Hemmelgarn; Nadia A Khan; Steven Grover; Donald W McKay; Thomas Wilson; Brian Penner; Ellen Burgess; Finlay A McAlister; Peter Bolli; Machael D Hill; Jeff Mahon; Martin G Myers; Carl Abbott; Ernesto L Schiffrin; George Honos; Karen Mann; Guy Tremblay; Alain Milot; Lyne Cloutier; Arun Chockalingam; Simon W Rabkin; Martin Dawes; Rhian M Touyz; Chaim Bell; Kevin D Burns; Marcel Ruzicka; Norman R C Campbell; Michel Vallée; Ramesh Prasad; Marcel Lebel; Sheldon W Tobe
Journal:  Can J Cardiol       Date:  2009-05       Impact factor: 5.223

View more
  2 in total

1.  Ambulatory blood pressure monitoring in resistant hypertension.

Authors:  Dimitrios Syrseloudis; Ioannis Andrikou; Eirini Andrikou; Kyriakos Dimitriadis; Christodoulos Stefanadis
Journal:  Int J Hypertens       Date:  2011-04-05       Impact factor: 2.420

2.  Patient-Centered Home Care Using Digital Medicine and Telemetric Data for Hypertension: Feasibility and Acceptability of Objective Ambulatory Assessment.

Authors:  Lorenzo A DiCarlo; Richard L Weinstein; Catherine B Morimoto; George M Savage; Gregory L Moon; Kityee Au-Yeung; Yoona A Kim
Journal:  J Clin Hypertens (Greenwich)       Date:  2016-02-18       Impact factor: 3.738

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.